Whanin Pharm환인제약
016580 · KOSPI · ₩016580 · 환인제약
- Market cap
- ₩190B
- Enterprise value
- ₩126B
- P/E
- 9.3×
- P/B
- 0.4×
- Dividend yield
- 2.9%
- ROE
- 4.8%
- Net margin
- 7.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−15.7% from the high
₩9,160Today: ₩10,030 – ₩10,300₩12,140
Returns
- 1W−1.9%
- 1M+1.7%
- 3M+4.7%
- 6M−12.8%
- YTD−9.6%
- 1Y−11.5%
- Volume today
- 21,193
- 0.9× the 20-day average
- Traded today
- ₩215M
- Listed shares
- 18,600,070
- EPS (12 months)
- ₩1,100
- Earnings yield 10.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumFlat1.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Whanin Pharm stock overview
Whanin Pharm (환인제약, KRX: 016580) is listed on KOSPI, in the Biotech & Pharma sector. The company manufactures and sells pharmaceuticals, primarily to hospitals, with psychiatric and neurological medicines accounting for more than 80% of total sales. Its shares closed at ₩10,230 on Oct 27, 2026, up 1.49% on the day, giving it a market value of ₩190B.
Key facts
- Market cap
- ₩190B
- Sector
- Biotech & Pharma
- Latest price change
- +1.49%
- As of
- Oct 27, 2026
- Main business
- The company manufactures and sells pharmaceuticals, primarily to hospitals, with psychiatric and neurological medicines accounting for more than 80% of total sales.
Quick answers about Whanin Pharm
- What does Whanin Pharm do?
- The company manufactures and sells pharmaceuticals, primarily to hospitals, with psychiatric and neurological medicines accounting for more than 80% of total sales. It operates as a single reporting segment in the pharmaceutical business and conducts most of its activities in South Korea. Its subsidiaries are engaged in pharmaceutical research and development and general distribution.
- What is the market cap of Whanin Pharm?
- The market capitalisation of Whanin Pharm was ₩190B at the close on Oct 27, 2026.
- Who are the largest shareholders of Whanin Pharm?
- According to the latest official filings, the largest reported holders are Lee Won-beom (23.27%, as of May 11, 2026); Lee Kwang-sik (23.27%, as of Oct 30, 2025); Fidelity Management & Research Company LLC (5.64%, as of Feb 19, 2025).
- When is the next earnings report from Whanin Pharm?
- Korean companies rarely announce results dates in advance. Based on when Whanin Pharm filed the same report in past years, its next 3q results is expected between Nov 12, 2026 and Nov 13, 2026.
- Does the National Pension Service own Whanin Pharm?
- Yes. The National Pension Service held 3.12% of Whanin Pharm shares as of Dec 31, 2025.
Company profile
The company manufactures and sells pharmaceuticals, primarily to hospitals, with psychiatric and neurological medicines accounting for more than 80% of total sales. It operates as a single reporting segment in the pharmaceutical business and conducts most of its activities in South Korea. Its subsidiaries are engaged in pharmaceutical research and development and general distribution.
Written by AI from the company's latest annual report.
- Korean name
- 환인제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 이광식, 이원범(각자 대표이사)
- Founded
- Dec 1982
- Listed
- Jul 1996
- Listed shares
- 18,600,070
- Fiscal year ends
- Month 12
- Website
- www.whanin.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Half-year report (Jun 2026)Aug 13, 2026
- Preliminary earnings (consolidated)Jul 29, 2026
- Disclosure of Corporate Governance ReportMay 29, 2026
- Quarterly report (Mar 2026)May 13, 2026
- 5%+ holding reportMay 11, 2026
Titles in Korean until English translations are added.
Also known as: Whanin Pharm / 환인제약 / 016580 / KRX:016580
Source: KRX statistical information